Zobrazeno 1 - 7
of 7
pro vyhledávání: '"John W.J. Huang"'
Publikováno v:
Oncotarget
// Tun Kiat Ko 1 , Charles T.H. Chuah 1,2 , John W.J. Huang 1 , King-Pan Ng 1 and S. Tiong Ong 1,2,3,4 1 Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore 2 Department of Haematology, Singapore General Hospital, Singap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd1c3593c1fd0bcd7a6b0cd426678709
http://europepmc.org/articles/PMC4253416
http://europepmc.org/articles/PMC4253416
Autor:
John W.J. Huang, Tun Kiat Ko, S. Tiong Ong, Seong Lin Khaw, King Pan Ng, Hui San Chin, David C.S. Huang, Charles Chuah
Publikováno v:
Oncotarget
Both germline polymorphisms and tumor-specific genetic alterations can determine the response of a cancer to a given therapy. We previously reported a germline deletion polymorphism in the BIM gene that was sufficient to mediate intrinsic resistance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8963ea2a785222a6d4141b83b4cd05e
https://pubmed.ncbi.nlm.nih.gov/26517680
https://pubmed.ncbi.nlm.nih.gov/26517680
Autor:
Allen Eng Juh Yeoh, John W.J. Huang, Nan Jiang, Sheila Xinxuan Soh, Joshua Yew Suang Lim, S. Tiong Ong
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e103435 (2014)
PLoS ONE
PLoS ONE
A broad range of anti-cancer agents, including glucocorticoids (GCs) and tyrosine kinase inhibitors (TKIs), kill cells by upregulating the pro-apoptotic BCL2 family member, BIM. A common germline deletion in the BIM gene was recently shown to favor t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d58a2001194c4288eb21411ad509a699
http://europepmc.org/articles/PMC4121131?pdf=render
http://europepmc.org/articles/PMC4121131?pdf=render
Autor:
Naoto Takahashi, V. S. Nadarajan, Yijun Ruan, Anbupalam Thalamuthu, Wing-Kin Sung, Xing Yi Woo, Hae Tha Mya, Sheila Soh, Xiaoan Ruan, Wen Chun Juan, Kazutoshi Isobe, Markus M. Nöthen, Wan-Teck Lim, John W.J. Huang, Hein Than, Yao Fei, L.Y. Yang, Chia-Tien Chang, Dianne Poh, Noan-Minh Chau, Axel M. Hillmer, Liang Piu Koh, Ai Leen Ang, Gee Fung How, Mei-Kim Ang, Yeow Tee Goh, Lay Cheng Lim, Tan Min Chin, Daniel Shao-Weng Tan, Wee Joo Chng, Balram Chowbay, Audrey S.M. Teo, Hiroyuki Mano, Ju Ee Seet, Niranjan Nagarajan, Quan Sing Ng, Shenli Zhang, Pramila N. Ariyaratne, Atif Shahab, Wan Ting Poh, Manabu Soda, Patrick Tan, Yasushi Yatabe, Kenichi Sawada, Vikrant Kumar, Ross A. Soo, Tien Yin Wong, Valere Cacheux-Rataboul, Charles Chuah, Eng Huat Tan, John Carson Allen, King Pan Ng, Wah Heng Lee, S. Tiong Ong, Tun Kiat Ko
Publikováno v:
Nature medicine. 18(4)
Tyrosine kinase inhibitors (TKIs) elicit high response rates among individuals with kinase-driven malignancies, including chronic myeloid leukemia (CML) and epidermal growth factor receptor-mutated non-small-cell lung cancer (EGFR NSCLC). However, th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36f59fffa8f03bafce17db3a749469cb
https://pubmed.ncbi.nlm.nih.gov/25295933
https://pubmed.ncbi.nlm.nih.gov/25295933
Publikováno v:
Blood. 122:3977-3977
Germline polymorphisms and tumor-specific genetic mutations together contribute to the behavior of human cancers, including the response to therapy. However, few specific models allow for the detailed study of how inherited and acquired genetic facto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::423b352a89f0ee993ea00d3946d95e89
https://doi.org/10.1182/blood.v122.21.3977.3977
https://doi.org/10.1182/blood.v122.21.3977.3977
Publikováno v:
Blood. 122:3978-3978
The advent of tyrosine kinase inhibitors (TKI) that specifically target BCR-ABL has significantly prolonged the life of patients with CML. We and others have previously shown that the BH3 mimetic ABT-737 or its clinical equivalent, ABT-263, can signi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::347de5185c0b8c96010318a7ca524b5f
https://doi.org/10.1182/blood.v122.21.3978.3978
https://doi.org/10.1182/blood.v122.21.3978.3978
Autor:
Yao Fei, Axel M. Hillmer, Yeow Tee Goh, Shenli Zhang, John Carson Allen, Pramila N. Ariyaratne, Kazutoshi Isobe, King Pan Ng, Markus M. Nöthen, Charles Chuah, Wah Heng Lee, Hiroyuki Mano, V. S. Nadarajan, Yijun Ruan, Eng Huat Tan, Vikrant Kumar, Niranjan Nagarajan, Noan-Minh Chau, Xiaoan Ruan, Atif Shahab, Manabu Soda, Yasushi Yatabe, S. Tiong Ong, Mei-Kim Ang, Wing-Kin Sung, Daniel Shao-Weng Tan, Wee Joo Chng, Dianne Poh, John W.J. Huang, Audrey S.M. Teo, Sheila Soh, Xing Yi Woo, Tien Yin Wong, Patrick Tan, Tan Min Chin, Kenichi Sawada, Tun-Kiat Ko, Lay Cheng Lim, Liang Piu Koh, Wan Ting Poh, Ross A. Soo, Ju Ee Seet, Wan-Teck Lim, Hein Than, Quan Sing Ng, Wen Chun Juan, L.Y. Yang, Naoto Takahashi, Anbupalam Thalamuthu, Valere Cacheux-Rataboul
Publikováno v:
Cancer Research. 72:1911-1911
The use of tyrosine kinase inhibitors (TKI) to target oncogenic kinases has led to remarkable responses in patients with chronic myeloid leukemia (CML) and EGFR-mutated non-small cell lung cancer (EGFR NSCLC). However, a significant subset of patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6fddafff38b2a27b18b42d272285f2c2
https://doi.org/10.1158/1538-7445.am2012-1911
https://doi.org/10.1158/1538-7445.am2012-1911